Mixed Lineage Kinase-c-Jun N-Terminal Kinase Axis: A Potential Therapeutic Target in Cancer | Zendy

Ajay Rana | Zendy; Basabi Rana | Zendy; Rajakishore Mishra | Zendy; Gautam Sondarva | Zendy; Velusamy Rangasamy | Zendy; Subhasis Das | Zendy; Navin Viswakarma | Zendy; Anumantha G. Kanthasamy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mixed Lineage Kinase-c-Jun N-Terminal Kinase Axis: A Potential Therapeutic Target in Cancer

Author(s) -

Ajay Rana,

Basabi Rana,

Rajakishore Mishra,

Gautam Sondarva,

Velusamy Rangasamy,

Subhasis Das,

Navin Viswakarma,

Anumantha G. Kanthasamy

Publication year - 2013

Publication title -

genes and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.883

H-Index - 71

eISSN - 1947-6027

pISSN - 1947-6019

DOI - 10.1177/1947601913485415

Subject(s) - cyclin dependent kinase 4 , map kinase kinase kinase , kinase , ask1 , protein kinase a , mitogen activated protein kinase kinase , cancer research , biology , cyclin dependent kinase 9 , map2k7 , cancer , cyclin dependent kinase 2 , protein kinase r , cell cycle , lineage (genetic) , microbiology and biotechnology , genetics , gene

Mixed lineage kinases (MLKs) are members of the mitogen-activated protein kinase kinase kinase (MAP3K) family and are reported to activate MAP kinase pathways. There have been at least 9 members of the MLK family identified to date, although the physiological functions of all the family members are yet unknown. However, MLKs in general have been implicated in neurodegenerative diseases, including Parkinson and Alzheimer diseases. Recent reports suggest that some of the MLK members could play a role in cancer via modulating cell migration, invasion, cell cycle, and apoptosis. This review article will first describe the biology of MLK members and then discuss the current progress that relates to their functions in cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research